OraSure Technologies to Commemorate World AIDS Day by Ringing NASDAQ Closing Bell
November 30 2020 - 7:00AM
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight
against HIV, today announced its plans to commemorate World AIDS
Day. On Tuesday, Dec. 1st, OraSure will ring the closing bell for
the NASDAQ Stock Market, in a virtual ceremony that will be
livestreamed.
“A year ago, on World AIDS Day 2019, it appeared
that eliminating the HIV epidemic was within our grasp. Today,
we’re in a far different place as COVID-19 has disrupted the
delivery of testing, services and care, reversing many of the gains
we’ve made,” said OraSure President and CEO, Stephen S. Tang, Ph.D.
“Today, on World AIDS Day 2020, it’s time to put a stake in the
ground: We cannot let the HIV epidemic take a back seat to
COVID-19. At OraSure, we are proud of the ways in which we are
meeting the global need for HIV diagnostics, and we are committed
to doing the same for COVID-19.”
To commemorate World AIDS Day globally, OraSure
also partnered with the MTV Staying Alive Foundation on a video
campaign, based around an African television series MTV Shuga,
which encourages young adults to take an HIV self-test.
Furthermore, in Kenya, the Ministry of Health has partnered with
OraSure to pilot electronic vending machines for HIV self-test
kits. The machines will launch on World AIDS Day. The widely used
OraQuick® HIV Self-Test was the first WHO-prequalified HIV
self-test in Sub-Saharan Africa.
To watch the livestream feed of the NASDAQ Closing Bell
Ceremony, go to
https://livestream.com/accounts/27896496/events/9408209 by 3:45
p.m. ET.
About OraSure Technologies HIV
Tests
The OraQuick® In-Home HIV Test is the first and
only oral fluid rapid over-the-counter (OTC) HIV test approved in
the U.S. The OraQuick® In-Home HIV Test can detect antibodies to
both HIV-1 and HIV-2 with an oral swab, providing a confidential
in-home testing option with results in as little as 20 minutes. It
is the first rapid diagnostic test for any infectious disease that
has been approved by the FDA for sale to the consumer market.
The OraQuick® HIV Self-Test (HIVST) is a rapid,
point-of-care test that allows an individual to detect antibodies
to both HIV-1 and HIV-2 with a simple oral swab and provides a
result in as little as 20 minutes in the privacy of an individual’s
home, at outreach testing settings, in the pharmacy or at community
based screening events. Based on the same OraQuick® platform that
is used for the FDA-approved OraQuick® In-Home HIV Test and the WHO
Prequalified OraQuick® Rapid HIV-1/2 Antibody Test used by health
care professionals worldwide, the platform has been used to test
millions in international markets.
The OraQuick ADVANCE® Rapid HIV-1/2 Antibody
Test is the first FDA approved, CLIA-waived, rapid point-of care
test that can detect antibodies to both HIV-1 and HIV-2 with
greater than 99 percent accuracy in as little as 20 minutes, using
an oral fluid, finger-stick or venipuncture whole blood, or plasma
sample.
UrSure, a wholly-owned subsidiary of OraSure,
offers diagnostic tests that measure adherence to HIV medications,
including pre-exposure prophylaxis or PrEP, the daily medication to
prevent HIV. This includes laboratory-based tests that can measure
levels of the medication in a patient’s urine or blood, as well as
several additional point of care products in development.
About OraSure Technologies
OraSure Technologies empowers the global
community to improve health and wellness by providing access to
accurate, essential information. Together with its wholly-owned
subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating
under the Diversigen brand), UrSure and Novosanis, OraSure provides
its customers with end-to-end solutions that encompass tools,
services and diagnostics. The OraSure family of companies is a
leader in the development, manufacture, and distribution of rapid
diagnostic tests, sample collection and stabilization devices, and
molecular services solutions designed to discover and detect
critical medical conditions. OraSure’s portfolio of products is
sold globally to clinical laboratories, hospitals, physician’s
offices, clinics, public health and community-based organizations,
research institutions, government agencies, pharma, commercial
entities and direct to consumers. For more information on OraSure
Technologies, please visit www.orasure.com.
Company contacts:
Sam MartinArgot Partners
212-600-1902OraSure@argotpartners.com
Jeanne Mell VP Corporate Communications 484-353-1575
media@orasure.com www.orasure.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Apr 2023 to Apr 2024